A5050651759- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Otitis Media and Relapsing Polychondritis
- Retinoids in leukemia and cellular processes
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Disorders and Syndromes
- Blood disorders and treatments
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Related Disorders
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Histiocytic Disorders and Treatments
- Sarcoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Renal and related cancers
- Vascular Anomalies and Treatments
- Respiratory Support and Mechanisms
- Pneumocystis jirovecii pneumonia detection and treatment
- Vascular Tumors and Angiosarcomas
Centre Hospitalier Universitaire de Lille
2014-2024
Université de Lille
2014-2024
Lille’s Cardiology Hospital
2015-2024
Institut de Biologie de Lille
2010-2024
Centre National de la Recherche Scientifique
2020-2023
Inserm
2014-2023
CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers
2020-2023
Université Paris Cité
2018-2023
Délégation Paris 7
2023
Institut pour la Recherche sur le Cancer de Lille
2014-2022
Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed question whether NPM1m MRD may be used as a predictive factor allogeneic stem cell transplantation (ASCT) benefit. Patients Methods Among 229 who were treated Acute Leukemia French Association 0702 (ALFA-0702) trial, evaluation was available 152 first remission. nonfavorable AML...
// Houria Debarri 1, 2, * , Delphine Lebon 3, Christophe Roumier 4 Meyling Cheok 4, 5 Alice Marceau-Renaut Olivier Nibourel Sandrine Geffroy Nathalie Helevaut 2 Philippe Rousselot 6 Bérengère Gruson 3 Claude Gardin 7 Marie-Lorraine Chretien 8 Shéhérazade Sebda Martin Figeac Céline Berthon Bruno Quesnel Nicolas Boissel 9 Sylvie Castaigne Hervé Dombret Aline Renneville Preudhomme 1 Hematology Department, Lille University Hospital, Lille, France...
Abstract Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that -TDs occur about 3% patients aged 18–60 years, mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics 59 adults -TD included young age (median 37 years), low bone marrow (BM) blast infiltration 25%), and high rates WT1 mutations (61%),...
Despite major treatment improvements over the past decades, pediatric acute myeloid leukemia (AML) is still a life-threatening malignancy with relapse rates up to 30% and survival below 75%. A better description of pattern molecular aberrations in childhood AML needed refine prognostication such patients. We report here comprehensive landscape using both high-throughput sequencing focused on 36 genes ligation-dependent RT-PCR 385 children de novo enrolled prospective ELAM02 trial we...
We investigated using a custom NGS panel of 149 genes the mutational landscape 64 consecutive adult patients with tyrosine kinase fusion-negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive myeloid neoplasm. At least one mutation was reported in 50/64 (78%) (compared to 8/44 (18%) idiopathic HE/HES/HE
Microtransplantation is a cellular therapy used in acute myeloid leukaemia and myelodysplastic syndromes as maintenance patients ineligible for regular allogeneic stem cell transplantation. We performed monocentric retrospective study of leukaemia, syndromes, chronic myelomonocytic who underwent microtransplantations at Nice University Hospital. analysed the evolution disease mutational status after microtransplantation. report 18 microtransplantation courses, with total 47 between February...
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential IDH1/2 mutations targets for assessment leukemia, since these collectively occur 15–20% cases leukemia and now represent druggable targets. We employed droplet digital polymerase chain reaction assays to quantify IDH1R132, IDH2R140, IDH2R172 on genomic DNA 322 samples from 103 adult patients with primary mutant enrolled Acute Leukemia...
Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged a factor chronic inflammatory background subsequent aging-associated diseases. The purpose this study was to identify biological (particularly leukocyte subtypes markers) associated with clinical deterioration (i.e.,...
ABCB1 is a member of the ATP binding cassette transporter family and high activity considered as poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation drug resistance remains unclear. We evaluated clinical parameters treatment response to standard chemotherapy 321 patients de novo AML. assessed multiple relationships activity—ex vivo resistance, gene expression, inhibitor quinine were evaluated. was observed 58% AML linked low white...
Abstract WT1 overexpression is frequently identified in acute myeloid leukemia (AML) and has been reported to be a potential marker for monitoring measurable residual disease (MRD). We evaluated the use of postinduction MRD level as prognostic factor, well interaction between response effect allogeneic stem cell transplantation (allo-SCT) first complete remission (CR). In ALFA-0702 trial, patients with AML, aged 18 59, had prospective quantification MRD. The occurrence ratio >2.5%...
Although acute myeloid leukemia (AML) with t(8;21) belongs to the favorable risk AML subset, relapse incidence may reach 30% in those patients. RUNX1-RUNX1T1 fusion transcript is a well-established marker for minimal residual disease (MRD) monitoring. In this study, we investigated feasibility and performances of DNA as MRD t(8;21). 17/22 patients t(8;21)-positive treated French CBF-2006 trial, breakpoints RUNX1 RUNX1T1 were identified using long-range PCR followed by next-generation...